Discussion In the current study, the potential benefits of L-carnitine supplementation in patients with COVID-19 disease have been evaluated
In Phase 1 studies, survodutide was generally well tolerated, with no significant safety or tolerability issues observed in either healthy individuals with overweight or obesity [87, 88]
Patients on Tirzepatide are already losing 20% of their body weight
Long-term continuous use without breaks may lead to reduced effectiveness
Huang, Y., Qing, X., Jiang, G., Chen, L., He, Q., Meng, X
tirzepatide, sold as Mounjaro and Zepbound, as well as Lilly's Trulicity, or dulaglutide, and Novo's older liraglutide, sold as Saxenda and Victoza